GlaxoSmithKline Pharmaceuticals Limited (BOM: 500660)

Market Cap	477.37B
Revenue (ttm)	35.07B
Net Income (ttm)	6.40B
Shares Out	169.41M
EPS (ttm)	37.77
PE Ratio	74.60
Forward PE	54.13
Dividend	32.00 (1.14%)
Ex-Dividend Date	May 31, 2024

Volume	2,865
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1,387.90 - 3,087.95
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;...

• Industry: Pharmaceutical Preparations
• Founded: 1924
• Employees: 3,211
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500660

Financial Performance

In 2023, GlaxoSmithKline Pharmaceuticals's revenue was 34.54 billion, an increase of 6.21% compared to the previous year's 32.52 billion. Earnings were 5.90 billion, a decrease of -3.39%.